

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A method of forming a drug eluting stent, the method comprising:

coupling a stent framework to a mandrel;
inserting the mandrel with stent framework into an open die set, the die set including a forming surface including a plurality of raised indentation forming portions;
closing the die set against the stent framework;
pressing the raised indentation portions into the stent framework to form indentions in the stent framework; and
inserting at least one drug polymer into the indentions formed in the stent framework.

Claim 2 (original): The method of claim 1 further comprising:
reopening the die set and repositioning the stent framework within the reopened die set, reclosing the die set and pressing the raised indentation forming portions into the stent framework.

Claim 3 (original): The method of claim 2 wherein the repositioning comprises rotating the mandrel with stent within the reopened die set.

Claim 4 (original): The method of claim 1 further comprising:
reopening the die set;
rotating the die set in relation to the stent on the mandrel; and
reclosing the die set to press the raised indentation portions into a different position on the stent framework.

Claim 5 (original): The method of claim 1 further comprising:
coupling a collar to the mandrel adjacent one end of the stent framework.

Claim 6 (original): The method of claim 1 wherein the raised indentation forming portions are formed by a process selected from the group consisting of: welding, photo chemical etching, lithography, bead blasting and electrodeposition.

Claim 7 (original): The method of claim 1 wherein inserting at least one drug polymer into the indentions comprises applying a drug polymer solution onto the stent and curing the stent to form a drug polymer coating.

Claim 8 (original): The method of claim 7 further comprising:
applying a polymer solution to the drug polymer coated stent; and
curing the stent to form a polymer cap coating.

Claim 9 (original): The method of claim 7 wherein the drug polymer solution contains at least one therapeutic agent.

Claim 10 (original): The method of claim 9 wherein the therapeutic agent is selected from the group consisting of an antisense agent, an antineoplastic agent, an antiproliferative agent, an antithrombogenic agent, an anticoagulant, an antiplatelet agent, an antibiotic, an anti-inflammatory agent, a therapeutic peptide, a gene therapy agent, a therapeutic substance, an organic drug, a pharmaceutical compound, a recombinant DNA product, a recombinant RNA product, a collagen, a collagenic derivative, a protein, a protein analog, a saccharide, a saccharide derivative, and a combination thereof.

Claim 11 (Currently Amended): The ~~[[stent]]~~ method of claim 8 wherein the cap coating comprises a polymer selected from the group consisting of a silicone-urethane copolymer, a polyurethane, a phenoxy, ethylene vinyl acetate, polycaprolactone, poly(lactide-co-glycolide), polylactide, polysulfone, elastin, fibrin, collagen, chondroitin sulfate, a biocompatible polymer, a biostable polymer, a biodegradable polymer, and a combination thereof.

Claim 12 to Claim 15 (Cancelled)